SHH · 603259.SS
WuXi AppTec Co., Ltd.
CN¥142.01-CN¥0.88 (-0.62%)
WuXi AppTec Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 18.2% below the high.
Loading market information…
SHZ · 300294.SZ · CNY
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 07:04 AM UTC. Cached market data; not a live quote.
One-year closing-price history · CNY. Historical prices are not a forecast.
China Resources Boya Bio-pharmaceutical Group Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 46.84% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
China Resources Boya Bio-pharmaceutical Group Co., Ltd.’s forward annual dividend is CN¥0.15 per share, paid semi-annual. The forward yield is 1.07% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
China Resources Boya Bio-pharmaceutical Group Co., Ltd.’s next earnings report is currently expected on Oct 30, 2026, with estimated earnings per share of CN¥0.05. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow China Resources Boya Bio-pharmaceutical Group Co., Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Established in 1993 and headquartered in Fuzhou, China, China Resources Boya Bio-pharmaceutical Group Co., Ltd. (formerly Boya Bio-pharmaceutical Group Co., Ltd.) is a comprehensive pharmaceutical enterprise operating across China. The company is engaged in the research, development, production, and sale of a diverse portfolio, primarily focusing on blood products, diabetes medications, and various biochemical and chemical pharmaceuticals. Its extensive range of blood-derived products includes human fibrinogen, human albumin, intravenous human immunoglobulin, rabies immunoglobulin, hepatitis B human immunoglobulin, and freeze-dried intravenous human immunoglobulin. For diabetes management, the company offers metformin hydrochloride (both tablets and enteric-coated versions), pioglitazone hydrochloride dispersible tablets, glimepiride tablets, and calcium dobesilate capsules. Additionally, it produces specialized injections such as compound osteotide, oxytocin, and heparin sodium, which are utilized across numerous medical fields, including general medicine, hepatitis treatment, gynecology, and immunomodulatory applications.
Latest available per-share figures in CNY. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:37 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| CN¥471.90M-4.09% vs estimate |
| Q1 2025 | Apr 24, 2025 | CN¥0.28+3.7% vs estimate | CN¥535.88M0.0% vs estimate |
|---|
| Q4 2024 | Mar 18, 2025 | -CN¥0.03-110.71% vs estimate | CN¥490.00M+22.81% vs estimate |
|---|
| Q3 2024 | Oct 24, 2024 | CN¥0.19-36.67% vs estimate | CN¥349.37M |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CN¥142.01-CN¥0.88 (-0.62%)
WuXi AppTec Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 18.2% below the high.
CN¥48.46-CN¥0.16 (-0.33%)
Jiangsu Hengrui Medicine Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 26.39% below the high.
HK$50.80+HK$0.15 (+0.3%)
Jiangsu Hengrui Pharmaceuticals Co.,Ltd’s quoted price sits in the lower half of its reported 52-week range, 37.25% below the high.
CN¥181.75+CN¥2.75 (+1.54%)
Shenzhen Mindray Bio-Medical Electronics Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 19.04% below the high.
HK$32.48-HK$0.60 (-1.81%)
Hansoh Pharmaceutical Group Company Limited’s quoted price sits in the lower half of its reported 52-week range, 26.55% below the high.
CN¥12.31-CN¥0.06 (-0.49%)
Beijing Tiantan Biological Products Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 34.14% below the high.
CN¥18.75-CN¥0.04 (-0.21%)
Tibet Cheezheng Tibetan Medicine Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 28.84% below the high.
CN¥9.40+CN¥0.02 (+0.21%)
Pacific Shuanglin Bio-pharmacy Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 42.75% below the high.
